A Phase I, Randomized, Open Label, 3-Way Cross-Over Study to Determine the Effect of a High-Fat Breakfast, a Low-Fat Breakfast and Fasting State on the Pharmacokinetics of a Single Oral Dose of 160 mg Regorafenib (BAY73-4506) in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 22 May 2013
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer; Renal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Bayer
- 27 May 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 29 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Actual initiation date (Oct 2009) added as reported by ClinicalTrials.gov.